| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kevin John Conway | Chief Financial Officer | 2026-02-02 | 72 | $5.64 | $406.08Sell |
| Yalonda Howze | INTERIM CEO PRESIDENT | 2026-02-02 | 495 | $5.64 | $2.79kSell |
| Geoff McDonough | Director | 2026-02-02 | 550 | $5.64 | $3.10kSell |
| Kevin John Conway | Chief Financial Officer | 2026-01-15 | 17 | $5.64 | $95.88Sell |
| Geoff McDonough | Director | 2026-01-15 | 137 | $5.64 | $772.68Sell |
| Yalonda Howze | CHIEF LEGAL OFFICER | 2026-01-15 | 99 | $5.64 | $558.36Sell |
| Geoff McDonough | Director | 2025-10-31 | 293 | $5.51 | $1.61kSell |
| Kevin John Conway | Chief Financial Officer | 2025-10-15 | 18 | $6.71 | $120.78Sell |
| Phillip Samayoa | CHIEF SCIENTIFIC OFFICER | 2025-10-15 | 34 | $6.71 | $228.14Sell |
| Geoff McDonough | PRESIDENT AND CEO | 2025-10-15 | 155 | $6.71 | $1.04kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Atlas Venture Fund X LP | 122.87% | 8,278,876 | $46.53M | Insider |
| Zone Healthcare Holdings LLC | 56.96% | 3,837,638 | $21.57M | Insider |
| William Seybold | 56.96% | 3,837,638 | $21.57M | Insider |
| Invus Public Equities LP | 41.77% | 2,814,191 | $15.82M | Insider |
| Wellington Biomedical Innovation Master Investors Cayman I LP | 31.35% | 2,112,546 | $11.87M | Insider |
| Casdin Capital LLC | 23.91% | 1,611,215 | $9.06M | Insider |
| James E. Flynn | 17.61% | 1,186,215 | $6.67M | Insider |
| Jason P. Rhodes | 17.32% | 1,166,937 | $6.56M | Insider |
| Atlas Venture Associates X LP | 17.32% | 1,166,937 | $6.56M | Insider |
| Atlas Venture Life Science Advisors LLC | 12.29% | 827,946 | $4.65M | Institution |